The European Patent Office (EPO) has issued a patent covering the intellectual rights to the composition and formulation of TNX-102 SL, Tonix Pharmaceuticals’ investigational under-the-tongue muscle relaxant now in pivotal clinical trials to treat fibromyalgia and other disorders.
The company is currently enrolling adults with fibromyalgia into the Phase 3 RELIEF (NCT04172831) study, testing TNX-102 SL as a sublingual tablet taken at bedtime. Criteria for eligible patients are available here; U.S. trial locations and contacts are here.
"The issuance of this European patent is an important step forward in our efforts to broaden our intellectual property estate on a global basis for TNX-102 SL," Seth Lederman, MD, president and chief executive officer of Tonix Pharmaceuticals, said in a press release.
The patent (EP2968992A2), "Eutectic Formulations of Cyclobenzaprine Hydrochloride and Mannitol," includes 14 claims pertaining to compositions comprisin